Related Experiment Video
Updated: Nov 24, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.3K
Additional baricitinib loading dose improves clinical outcome in COVID-19
Md Jahidul Hasan1, Raihan Rabbani2, Ahmad Mursel Anam3
1Clinical Pharmacy Services, Department of Pharmacy, Square Hospitals Ltd, 18/F Bir Uttam Qazi Nuruzzaman Sarak, West Panthapath, Dhaka-1205, Bangladesh.
Open Medicine (Warsaw, Poland)
|December 28, 2020
Summary
Adding a loading dose of baricitinib to standard treatment improved outcomes for patients with moderate-to-severe COVID-19 pneumonia. This approach reduced recovery time and intensive care unit admissions for pneumonia patients.
Area of Science:
- Immunology
- Pharmacology
- Infectious Diseases
Background:
- COVID-19 pneumonia presents a high mortality risk globally.
- Effective anti-inflammatory treatments for COVID-19 pneumonia remain a challenge.
- Baricitinib, a Janus kinase inhibitor, shows promise for treating COVID-19 pneumonia.
Purpose of the Study:
- To compare the clinical outcomes of moderate-to-severe COVID-19 pneumonia treated with baricitinib, with or without a loading dose.
- To evaluate the efficacy of an additional loading dose of baricitinib in COVID-19 pneumonia management.
Main Methods:
- A prospective case-control study involving 37 adult patients with moderate-to-severe COVID-19 pneumonia.
- Control group (17 patients): received 4 mg oral daily baricitinib.
- Case group (20 patients): received an 8 mg oral loading dose plus 4 mg daily baricitinib.
Main Results:
- The case group (with loading dose) showed a shorter median time to achieve blood oxygen saturation ≥95% and normal breathing.
- Intensive care unit (ICU) admission rates were lower in the case group (10%) compared to the control group (29.4%) (P < 0.05).
- Mechanical ventilation support was also lower in the case group (5%) versus the control group (11.8%) (P > 0.05).
Conclusions:
- An additional loading dose of baricitinib significantly improved clinical outcomes in patients with COVID-19 pneumonia.
- This regimen may be a more effective strategy for managing moderate-to-severe COVID-19 pneumonia.
- Baricitinib loading dose warrants further investigation for COVID-19 treatment protocols.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
328
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
328
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
299
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
299
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
307
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
307
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
103
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
103
01:26Pulmonary Tuberculosis IV
293
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
293
01:24Rational Dosage Regimen: Maintenance Dose and Loading Dose
4.9K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.9K